Pricing Log in Create free account
Friday 6 November 2026 Export TGTX’s income statement to Excel — free account

TG Therapeutics, Inc.

TGTX Healthcare Biotechnology

TG Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $616.3 million, up 87.3% from fiscal 2024.

Revenue
+70.3%
EPS
−73.7%
Free cash flow
+427.1%
Total debt
+204.2%

Quarter to June 2026, against a year earlier

59.51 1.53 +2.64%
Market cap
$8.9B
P/E
19.1×
Fwd P/E
62.4×
Dividend yield
—
F-score
5/9
Altman Z
6.29
Beneish M
0.80
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

TG Therapeutics, Inc. 10-K filed Mar 3, 2025

Fiscal year 2024 · Period ended Dec 31, 2024 · Filed · accepted 4:02 PM ET · Document on sec.gov · Filing index

Nothing in this filing raised a red flag. The document itself is on sec.gov.

Read the filing on sec.gov